Inflamed lymphomas, such as cHL, PMBCL, PCNSL, and PTL, are highly responsive to ICI therapy due, in part, to robust T-cell infiltrates, high PD-1/PD-L1 expression, and relatively high TMBs. Here, CD274 is linked to primary central nervous system lymphoma.